Melane Sampson, Author at BioTuesdays

Feature

PetVivo improving the lives of pets and athlete animals through joint health and mobility

PetVivo Holdings (PetVivo Animal Health) (OTCQX: PTEV; OTCID: PETVW) is adapting human regenerative therapies for the management of osteoarthritis (OA) and other joint disorders in companion and athlete animals. The...

January 6, 2026

Developments

Polyrizon reports positive preclinical results of PL-14 vs HPMC

Polyrizon (NASDAQ: PLRZ) has announced new results from a preclinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an...

January 5, 2026

Developments

MetaVia reports positive results from Phase 1b trial of DA-1726 in metabolic disease

MetaVia (NASDAQ: MTVA) has announced positive, statistically significant results from the eight-week, non-titrated, 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel dual...

January 5, 2026

Developments

Hoth expands IP portfolio with filing of two patent applications

Hoth Therapeutics (NASDAQ: HOTH) has announced the filing of two U.S. provisional patent applications to expand its IP portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin...

January 5, 2026

Developments

Annovis launches OLE study in Parkinson’s disease

Annovis Bio (NYSE: ANVS) has announced it will begin an open-label extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in Parkinson’s disease (PD) patients. The study aims...

December 19, 2025

Developments

Altimmune’s pemvidutide achieves key measures of success at 48 weeks in MASH trial

Altimmune (NASDAQ: ALT) has announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated...

December 19, 2025

Executive Moves

PureTech appoints Robert Lyne as CEO

PureTech Health (NASDAQ: PRTC; LSE: PRTC) has announced the appointment of Robert Lyne as chief executive officer (CEO), and member of the board of directors, effective immediately. Mr. Lyne has served as interim CEO...

December 18, 2025

Developments

Ovid reports results of OV350 IV study

Ovid Therapeutics (NASDAQ: OVID) has announced that its Phase 1 study of OV350—the first direct activator of potassium chloride cotransporter 2 (KCC2) to be dosed in humans—administered intravenously (IV), has met its...

December 18, 2025

Developments

Tiziana doses first patient in Phase 2 trial of intranasal foralumab in AD

Tiziana Life Sciences (NASDAQ: TLSA) has announced that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease...

December 17, 2025

Developments

VYNE and Yarrow announce merger agreement

VYNE Therapeutics (NASDAQ: VYNE) has announced that it has entered into a merger agreement with closely held Yarrow Bioscience, with the combined companies expected to operate as Yarrow Bioscience under the ticker...

December 17, 2025

Author - Melane Sampson

PetVivo improving the lives of pets and athlete animals through joint health and mobility

Polyrizon reports positive preclinical results of PL-14 vs HPMC

MetaVia reports positive results from Phase 1b trial of DA-1726 in metabolic disease

Hoth expands IP portfolio with filing of two patent applications

Annovis launches OLE study in Parkinson’s disease

Altimmune’s pemvidutide achieves key measures of success at 48 weeks in MASH trial

PureTech appoints Robert Lyne as CEO

Ovid reports results of OV350 IV study

Tiziana doses first patient in Phase 2 trial of intranasal foralumab in AD

VYNE and Yarrow announce merger agreement

Subscribe